QSAR and molecular docking study on the biological activity of levofloxacin and thiodiazole histone deacetylase inhibitors

Document Type : Research Article


1 School of Chemistry and Chemical Engineering, Xuzhou Institute of Technology, Xuzhou, China

2 School of Foreign Languages, Xuzhou Institute of Technology, Xuzhou, China


Using quantitative structure-activity relationship (QSAR) and molecular docking to study the interaction between levofloxacin and thiadiazole histone deacetylase inhibitors. The molecular electrical distance vector (MEDV) and multiple linear regression (MLR) were used to study the relationship between the structure and activity of compounds. The three equations obtained by multiple linear regression, their R2 = 0.976, 0.985 and 0.976, and their Rcv2 = 0.949, 0.977 and 0.932. The structures that affect HDAC1 and HDAC6 activity are -O- and -S-, and the structures that affect HDAC2 are -C- and -N-. Finally, molecular docking is used to study the binding of receptors and drug molecules to provide guidance for future drug design.


[1] I. A. Khan, S. Siddiqui and S. Rehmani, Fluoroquinolones inhibit HCV by targeting its helicase. Antivir. Ther., 17 (2012) 467-476.
[2] B. C. Smith and J. M. Denu, Chemical mechanisms of histone lysine and arginine modifications. Biochim. Biophys. Acta, 17 (2009) 45-57.
[3] M. J. Lai, H. L. Huang and S. L. Pan, Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide) indoles as potent histone deacetylase inhibitors with antitumor activity in vivo. J. Med. Chem., 55 (2012) 3777-3791.
[4] F. F. Wagner, D. E. Olson, and J. P. Gale, Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif. J. Med. Chem., 56 (2013) 1772-1776.
[5] H. Y. Lee, A. C. Tsai and M. C. Chen, Azaindolyl sulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells. J. Med. Chem., 57 (2014) 4009-4022.
[6] C. Tang, C. H. Li and S. L. Zhang, Novel bioactive hybrid compound dual targeting estrogen receptor and histone deacetylase for the treatment of breast cancer. J. Med. Chem., 58 (2015) 4550-4572.
[7] Y. W. Yao, H. Q. Yao and S. Jiang, Progress in clinical study of histone deacetylases inhibitors as anticancer agents .Chin. J. New. Drugs., 22 (2013) 294-299.
[8] P. Guan, X. Hou and L. Wang, Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif. Bioorg. Med. Chem., 22 (2014) 5766−5775.
[9] Y. M. Tan, W. Y. Huang and N. F. Yu, Structure-activity relationships of histone deacetylase inhibitors. Acta Pharm. Sin., 44 (2009) 1072-1083.
[10] S. Q. Xie, and Y. S. Chen, Part IV. Synthesis and antitumor evaluation of s-triazolothiadiazines and pyrazolos-triazoles derived from criproxacin. Acta Pharm. Sin., 47 (2012) 66-71.
[11] L. Z. Gao Y. S. Xie and T. Li, Synthesis, antitumor activity and SAR of C-3 oxadiazole sulfanylacetyl hydrazone-substituted fluoroquinolone analogues. Acta Pharm. Sin., 49 (2014) 1694-1698.
[12] Y. Itoh, and T. Suzuki, Isoform-selective histonedeacetylase inhibitors. Curr. Pharm. Des., 14 (2008) 529-544.
[13] J. Senger, J. Melesina and M. Marek, Synthesis and biological investigation of oxazole hydroxamatesas highly selective histone deacetylase 6 (HDAC6) inhibitors. J. Med. Chem., 59 (2016) 1545-1555.
[14] J. K. Murray and C. Balan, Dipeptidylquinolone derivatives inhibit hypoxia inducible factor-1 prolyl hydroxylases-1, -2, and -3 with altered selectivity. J. Comb. Chem., 12 (2010) 676-686.
[15] X. L. Jiang, Y. B. Cui and S. H. Cao, Progress in research on quinolone antibacterials. Chin. J. Antibiot., 36 (2011) 255-263.
[16] H. Li, X. Han and D. W. Li, Synthesis and anti-tumor activity of levofloxacin-thiadiazole histone deacetylase inhibitor conjugates. Acta Pharm. Sinica, 52 (2017) 582-591.
[17] L. B. Kier and L. H. Hall, An electrotopological-state index for atoms in molecules. Pharm. Res., 7 (1990) 801-807.